These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 2208183)

  • 1. Apomorphine in the diagnosis and treatment of parkinsonian tremor.
    Hughes AJ; Lees AJ; Stern GM
    Clin Neuropharmacol; 1990 Aug; 13(4):312-7. PubMed ID: 2208183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subcutaneous apomorphine in parkinsonian on-off oscillations.
    Stibe CM; Lees AJ; Kempster PA; Stern GM
    Lancet; 1988 Feb; 1(8582):403-6. PubMed ID: 2893200
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of subcutaneous apomorphine on tremor in idiopathic Parkinson's disease.
    Hellmann MA; Sabach T; Melamed E; Djaldetti R
    Biomed Pharmacother; 2008; 62(4):250-2. PubMed ID: 17967525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beginning-of-dose motor deterioration following the acute administration of levodopa and apomorphine in Parkinson's disease.
    Merello M; Lees AJ
    J Neurol Neurosurg Psychiatry; 1992 Nov; 55(11):1024-6. PubMed ID: 1469397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Continuous subcutaneous apomorphine as replacement for levodopa in severe parkinsonian patients after surgery.
    Broussolle E; Marion MH; Pollak P
    Lancet; 1992 Oct; 340(8823):859-60. PubMed ID: 1357288
    [No Abstract]   [Full Text] [Related]  

  • 6. Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon.
    Colosimo C; Merello M; Hughes AJ; Sieradzan K; Lees AJ
    J Neurol Neurosurg Psychiatry; 1996 Jun; 60(6):634-7. PubMed ID: 8648329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apomorphine infusion and the long-duration response to levodopa in advanced Parkinson's disease.
    Stocchi F; Berardelli A; Vacca L; Barbato L; Monge A; Nordera G; Ruggieri S
    Clin Neuropharmacol; 2003; 26(3):151-5. PubMed ID: 12782918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.
    Deleu D; Hanssens Y; Northway MG
    Drugs Aging; 2004; 21(11):687-709. PubMed ID: 15323576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Task Specific Tremor in Parkinson's Disease Responds to Apomorphine.
    Ondo WG; Koneru V; Arif C
    Tremor Other Hyperkinet Mov (N Y); 2023; 13():20. PubMed ID: 37275945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subcutaneous apomorphine in the treatment of Parkinson's disease.
    Frankel JP; Lees AJ; Kempster PA; Stern GM
    J Neurol Neurosurg Psychiatry; 1990 Feb; 53(2):96-101. PubMed ID: 2313313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sublingual apomorphine solution in Parkinson's disease.
    Panegyres PK; Graham SJ; Williams BK; Higgins BM; Morris JG
    Med J Aust; 1991 Sep; 155(6):371-4. PubMed ID: 1921784
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Subcutaneous administration of apomorphine in motor fluctuations in Parkinson's disease].
    Pollak P; Champay AS; Gaio JM; Hommel M; Benabid AL; Perret J
    Rev Neurol (Paris); 1990; 146(2):116-22. PubMed ID: 2320817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apomorphine for motor fluctuations and freezing in Parkinson's disease.
    Corboy DL; Wagner ML; Sage JI
    Ann Pharmacother; 1995 Mar; 29(3):282-8. PubMed ID: 7606075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological Treatment of Tremor in Parkinson's Disease Revisited.
    Pirker W; Katzenschlager R; Hallett M; Poewe W
    J Parkinsons Dis; 2023; 13(2):127-144. PubMed ID: 36847017
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Motor response following repeated apomorphine administration is reduced in Parkinson's disease.
    Grandas F; Obeso JA
    Clin Neuropharmacol; 1989 Feb; 12(1):14-22. PubMed ID: 2713864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Challenge tests to predict the dopaminergic response in untreated Parkinson's disease.
    Hughes AJ; Lees AJ; Stern GM
    Neurology; 1991 Nov; 41(11):1723-5. PubMed ID: 1944899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apomorphine test to predict dopaminergic responsiveness in parkinsonian syndromes.
    Hughes AJ; Lees AJ; Stern GM
    Lancet; 1990 Jul; 336(8706):32-4. PubMed ID: 1973218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of motor response to apomorphine and levodopa in Parkinson's disease.
    Kempster PA; Frankel JP; Stern GM; Lees AJ
    J Neurol Neurosurg Psychiatry; 1990 Nov; 53(11):1004-7. PubMed ID: 2283512
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease.
    Chen JJ; Obering C
    Clin Ther; 2005 Nov; 27(11):1710-24. PubMed ID: 16368444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subcutaneous apomorphine in Parkinson's disease: response to chronic administration for up to five years.
    Hughes AJ; Bishop S; Kleedorfer B; Turjanski N; Fernandez W; Lees AJ; Stern GM
    Mov Disord; 1993 Apr; 8(2):165-70. PubMed ID: 8474483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.